Former FDA Associate Commissioner Peter Pitts is president of the Center for Medicine in the Public Interest. Herve Le Louet is president of the Council for International Organizations of Medical Sciences.
Rising healthcare costs, coupled with high-profile stories of price gouging at some small pharmaceutical companies, have left consumers feeling ripped off
Anyone who thinks that the argument over off-label communications is just about marketing and sales is looking at the issue through very narrow blinders
A report released by Public Citizen and Carleton University urges Congress to allow Medicare to negotiate innovator drug prices and introduce mandatory generic substitution for all Medicare Part D plans. And Sen. Bernie Sanders (I-Vt.) has called for “wartime powers” to break the patents on drugs. First off, allowing the feds to negotiate Part D…
In years past pharma marketers had to check themselves before conveying off-label product claims, even though those off-label uses had long since become standards of care. But in recent months the FDA has signaled a willingness to open the off-label information floodgates. Former FDA Associate Commissioner Peter Pitts
explains exactly why this matters
Safety information is knowledge. And, in the pursuit of public health, knowledge is power
Demonizing new treatments distracts from the real problem: policies that focus on the near-term
A patient who is diagnosed earlier and receives the most efficacious treatment is the least expensive
At last the FDA has offered some semblance of guidance for digital promotional activities in the medical space. Was it worth the wait? And will it change anything? Peter Pitts picks it apart
It’s fast becoming an n of 1 world, where every disease is an orphan disease and success is measured by individual outcomes
